secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001829126-25-006210
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc secures $2.5M NIH grants for NEO212; finalizes $50M Quazar partnership
----------------------------------------------------------------------------

- Awarded two NIH STTR grants totaling $2.5M to advance NEO212 in gliomas and leukemia.
- $400K Phase 1 grant supports NEO212 preclinical study in AML; $2.1M Phase 2 grant targets newly diagnosed gliomas.
- NuroMENA Holdings Ltd. incorporated by Abu Dhabi Global Market, clearing all contingencies for $50M investment from Quazar Investment.
- Partnership will fund CNS platform launch in MENA region and accelerate NEO212/NEO100 clinical programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625006210/0001829126-25-006210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625006210/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-006210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer